These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 2965613

  • 1. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
    Galivan J, Nimec Z, Rhee M, Boschelli D, Oronsky AL, Kerwar SS.
    Cancer Res; 1988 May 01; 48(9):2421-5. PubMed ID: 2965613
    [Abstract] [Full Text] [Related]

  • 2. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.
    Galivan J, Nimec Z, Rhee M.
    Cancer Res; 1987 Oct 15; 47(20):5256-60. PubMed ID: 2958130
    [Abstract] [Full Text] [Related]

  • 3. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A, Galivan J, Beardsley GP, Bader H, O'Connor BM, Russello O, Moroson BA, DeYarman MT, Kerwar SS, Freisheim JH.
    Cancer Res; 1992 Apr 15; 52(8):2148-55. PubMed ID: 1313737
    [Abstract] [Full Text] [Related]

  • 4. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS, Galivan J, Wright JE, Rosowsky A.
    Mol Pharmacol; 1994 Apr 15; 45(4):783-91. PubMed ID: 7514264
    [Abstract] [Full Text] [Related]

  • 5. The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase.
    Galivan J, Rhee MS, Johnson TB, Chou TC, Nair MG, Bunni M, Priest D.
    Adv Enzyme Regul; 1989 Apr 15; 28():13-21. PubMed ID: 2624172
    [Abstract] [Full Text] [Related]

  • 6. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM.
    Mol Pharmacol; 1995 Sep 15; 48(3):459-71. PubMed ID: 7565626
    [Abstract] [Full Text] [Related]

  • 7. The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase.
    Galivan J, Rhee MS, Johnson TB, Dilwith R, Nair MG, Bunni M, Priest DG.
    J Biol Chem; 1989 Jun 25; 264(18):10685-92. PubMed ID: 2525127
    [Abstract] [Full Text] [Related]

  • 8. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
    Takemura Y, Ohnuma T.
    Mt Sinai J Med; 1992 Oct 25; 59(5):419-24. PubMed ID: 1435841
    [Abstract] [Full Text] [Related]

  • 9. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
    Smith SG, Lehman NL, Moran RG.
    Cancer Res; 1993 Dec 01; 53(23):5697-706. PubMed ID: 8242626
    [Abstract] [Full Text] [Related]

  • 10. Quantitation of folic acid enhancement of antifolate synergism.
    Gaumont Y, Kisliuk RL, Parsons JC, Greco WR.
    Cancer Res; 1992 Apr 15; 52(8):2228-35. PubMed ID: 1532766
    [Abstract] [Full Text] [Related]

  • 11. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G, Moroson BA, Cashmore AR, Russello O, Mayer JR, Galivan J, Bunni MA, Priest DG, Beardsley GP.
    Cancer Res; 1995 Feb 01; 55(3):566-73. PubMed ID: 7834626
    [Abstract] [Full Text] [Related]

  • 12. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
    Westerhof GR, Rijnboutt S, Schornagel JH, Pinedo HM, Peters GJ, Jansen G.
    Cancer Res; 1995 Sep 01; 55(17):3795-802. PubMed ID: 7641196
    [Abstract] [Full Text] [Related]

  • 13. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
    Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM.
    Cancer Res; 1997 Mar 15; 57(6):1116-23. PubMed ID: 9067281
    [Abstract] [Full Text] [Related]

  • 14. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL, Alison DL, Calvert AH, Harrap KR.
    Cancer Res; 1986 Jun 15; 46(6):2810-5. PubMed ID: 2938731
    [Abstract] [Full Text] [Related]

  • 15. Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells.
    Rhee MS, Balinska M, Bunni M, Priest DG, Maley GF, Maley F, Galivan J.
    Cancer Res; 1990 Jul 01; 50(13):3979-84. PubMed ID: 2162250
    [Abstract] [Full Text] [Related]

  • 16. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
    Jackman AL, Taylor GA, O'Connor BM, Bishop JA, Moran RG, Calvert AH.
    Cancer Res; 1990 Sep 01; 50(17):5212-8. PubMed ID: 2386929
    [Abstract] [Full Text] [Related]

  • 17. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity.
    Rhee MS, Wang Y, Nair MG, Galivan J.
    Cancer Res; 1993 May 15; 53(10 Suppl):2227-30. PubMed ID: 7683570
    [Abstract] [Full Text] [Related]

  • 18. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
    Matherly LH, Barlowe CK, Goldman ID.
    Cancer Res; 1986 Feb 15; 46(2):588-93. PubMed ID: 2416428
    [Abstract] [Full Text] [Related]

  • 19. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
    Temmink OH, Hoogeland MF, Fukushima M, Peters GJ.
    Cancer Chemother Pharmacol; 2006 Jan 15; 57(2):171-9. PubMed ID: 16010590
    [Abstract] [Full Text] [Related]

  • 20. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
    Sokoloski JA, Beardsley GP, Sartorelli AC.
    Cancer Res; 1989 Sep 01; 49(17):4824-8. PubMed ID: 2758415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.